RxDoctor Payments DataLook up a doctor →

Chukwuemeka Chima, MD

Infectious Disease · Fayetteville, NCNPI 1962494377

Payments from drug & device makers

$20,981in general payments, 2019–2025

Across 913 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$5K
  • Paratek Pharmaceuticals, Inc.$4K
  • Gilead$3K
  • AbbVie$2K
  • Melinta Therapeutics, LLC$1K
  • Merck$1K
  • plus $5K from 25 others

What the payments were for

  • Consulting fees$1000%
  • Speaking & faculty fees$3,01514%
  • Travel & lodging$2011%
  • Food & beverage$17,19382%
  • Education$4462%
  • Gifts$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,981 in reported general payments places this provider in the 80th percentile of 250 infectious disease providers in North Carolina.

See all infectious disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$491,503
Medicare patients
638
Services billed
31,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala194$801,984
DovatoDolutegravir Sodium/Lamivudine125$388,271
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf44$213,138
CabenuvaCabotegravir/Rilpivirine24$174,311
OdefseyEmtricitab/Rilpiviri/Tenof Ala44$166,789
TriumeqAbacavir/Dolutegravir/Lamivudi37$165,133
GenvoyaElviteg/Cob/Emtri/Tenof Alafen33$151,813
JulucaDolutegravir/Rilpivirine34$132,351
TivicayDolutegravir Sodium20$47,943
IsentressRaltegravir Potassium18$39,980
DescovyEmtricitabine/Tenofov Alafenam13$28,586
PifeltroDoravirine12$21,141
VemlidyTenofovir Alafenamide11$15,436
Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium12$7,677
Darunavir11$6,695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy, Vemlidy$2,795$997,819251 claims
Viiv Healthcare CompanyDovato, Cabenuva, Triumeq, Juluca, Tivicay$4,676$908,009240 claims
Janssen Products, LPSymtuza$224$213,13844 claims
MerckIsentress, Pifeltro$1,278$61,12130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 250 infectious disease providers in North Carolina.

Other infectious disease in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →